Compare VRAR & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAR | CLDI |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 9.9M |
| IPO Year | 2021 | N/A |
| Metric | VRAR | CLDI |
|---|---|---|
| Price | $1.03 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.62 | N/A |
| AVG Volume (30 Days) | ★ 101.7K | 81.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,488,209.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.60 | N/A |
| 52 Week Low | $0.96 | $1.10 |
| 52 Week High | $7.00 | $23.16 |
| Indicator | VRAR | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 47.63 |
| Support Level | $1.03 | $1.41 |
| Resistance Level | $1.16 | $1.54 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 59.09 |
The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.